• Teladoc Health reported third quarter 2026 sales of US$605.1 million, with the quarterly net loss narrowing to US$26.93 million and basic loss per share from continuing operations at US$0.15.
• The company paired softer year to date sales with a smaller net loss and a fresh revenue and loss per share outlook, providing a clearer view of how Teladoc Health is balancing demand, pricing and cost control.
• We will examine how Teladoc Health’s investment narrative aligns with the new guidance range for revenue and net loss.

Spot opportunities across telehealth and adjacent care platforms by scanning the hand picked 35 healthcare AI stocks. These stocks reflect the balance of growth potential and ongoing losses that investors are weighing with Teladoc Health.

Teladoc Health Investment Narrative Recap

To hold Teladoc Health long term, an investor has to believe virtual care can support a large, recurring insurance and employer led business, even while BetterHelp digests its shift away from pure cash pay therapy. The latest quarter shows sales easing but losses shrinking, so the nearer term story still leans on efficiency and mix rather than rapid expansion.

The updated outlook keeps the focus on one key catalyst: Teladoc One and broader Integrated Care adoption. It also underscores one key risk: pressure on BetterHelp margins as insured programs scale. Guidance for a smaller full year loss per share matters more than the modest revenue step down, which looks incremental rather than thesis breaking.

The fresh full year 2026 guidance is the piece that really matters around this earnings release. Management now expects revenue between US$2,441 million and US$2,935 million, with a net loss per share between US$0.95 and US$0.75. That bracketed range highlights how much execution on cost control and utilization will drive results over the next few quarters.

For the upcoming fourth quarter, Teladoc Health is guiding to US$569 million to US$615 million in revenue and a net loss per share between US$0.23 and US$0.03. Those figures tie directly into the catalysts investors are watching: the shift to visit based Integrated Care, the build out of insured BetterHelp, and whether AI tools and automation can keep losses moving lower even if sales stay roughly flat.

Teladoc Health's narrative projects US$2.4b revenue and US$172.5 million earnings by 2029. This implies fairly flat yearly revenue performance and an earnings increase of about US$327 million from the current loss of US$154.8 million.

Uncover how Teladoc Health's fair value indicates a 9% potential downside to its current price, which leaves little room for error.

Exploring Other Perspectives

One alternate angle puts Teladoc Health’s free cash flow in the spotlight. Bullish analysts were working off 2025 free cash flow of US$167 million and a 2026 outlook of US$130 million to US$170 million, so they viewed earnings of US$83.5 million by 2029 as realistic. You can now ask whether this latest guidance keeps that cash story intact or forces a rethink of those optimistic assumptions.

Explore 4 other Teladoc Health fair value estimates, including one that suggests up to 71% upside from the current price.

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Teladoc Health research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• See our latest analysis for Teladoc Health. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Teladoc Health's overall financial health at a glance.

Looking for more Teladoc Health style investment ideas?

If Teladoc Health has you thinking about where recurring revenue, cash burn, and balance sheet strength intersect, it can help to widen the search and compare it with other businesses facing similar trade offs.

• For investors who want potential upside without paying full price for quality, check out a curated group of undervalued companies through the Simply Wall St screener focused on 39 high quality undervalued stocks.
• If income and resilience matter more than rapid expansion, focus on businesses built around reliable shareholder payouts by scanning a set of 8 dividend fortresses using the screener.
• When capital preservation and financial robustness are at the top of your checklist, start with the screener highlighting a 29 resilient stocks with low risk scores and compare how their risk profiles stack up against Teladoc Health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.